What is Xilis?
Xilis operates at the intersection of advanced biotechnology and artificial intelligence, providing a scalable solution for cancer care through its MicroOrganoSphere (MOS) platform. By creating miniature patient tumors that accurately replicate the heterogeneity and microenvironment of actual human cancers, Xilis enables high-throughput preclinical modeling and clinical patient selection. This capability is critical for the development of the Xilis Response Score, an AI-driven tool designed to provide oncologists with actionable, timely data to improve patient outcomes. Beyond clinical applications, the company serves as a vital partner for pharmaceutical firms, streamlining the drug discovery pipeline by offering a more authentic representation of tumor biology than traditional models.
How much funding has Xilis raised?
Xilis has raised a total of $92M across 2 funding rounds:
Angel/Seed
$3M
Series A
$89M
Angel/Seed (2019): $3M with participation from Pear, Felicis Ventures, Liquid 2 Ventures, 8VC, and Guardant Health
Series A (2022): $89M led by GV, Pear Ventures, EQT Life Sciences, Mubadala Capital Management, FPV Ventures, Catalio Capital Management, Life Sciences Partners, and Alexandria Venture Investments
Key Investors in Xilis
Pear
Pear VC is a venture capital firm specializing in pre-seed and seed investments, providing founders with essential resources like talent recruitment and go-to-market strategies to build high-growth companies.
GV
GV is a global venture capital firm that invests across multiple stages and sectors, with a strong focus on life sciences, enterprise solutions, and frontier technology innovations.
Catalio Capital Management
Catalio Capital Management is a New York-based firm specializing in breakthrough biomedical technology, leveraging a deep network of venture partners to support healthcare companies across private and public markets.
What's next for Xilis?
With the support of major institutional backers, Xilis is poised to transition from its foundational development phase into a broader commercial and clinical scaling stage. The recent capital injection will likely be directed toward expanding the utility of the MOS technology across diverse oncology indications and strengthening the company's AI-driven diagnostic infrastructure. As the firm continues to integrate its platform into clinical workflows, the focus will remain on establishing the Xilis Response Score as a standard of care, while simultaneously deepening its strategic partnerships within the global pharmaceutical industry to accelerate the next generation of cancer therapeutics.
See full Xilis company page
